This insight opens up promising avenues for enhancing the efficacy of cellular therapies by engineering T cells with gain-of-function EZH2 mutants, potentially enabling these cells to better navigate the metabolic challenges posed by the tumor milieu and resist pharmacological stressors.200. The gene discussed is EZH2; the disease is neoplasm.